Back to top
more

Vertex Pharmaceuticals (VRTX)

(Delayed Data from NSDQ)

$474.16 USD

474.16
813,290

-7.10 (-1.48%)

Updated Sep 18, 2024 04:00 PM ET

After-Market: $475.69 +1.53 (0.32%) 5:46 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (81 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

The company’s main area of focus is cystic fibrosis (CF). The company’s lead marketed products are Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor), Symdeko/Symkevi (tezacaftor in combination with ivacaftor), Orkambi (lumacaftor in combination with ivacaftor) and Kalydeco (ivacaftor), which are collectively approved to treat the majority of the people with CF in North America, Europe and Australia. Trikafta, Vertex’s triple combination regimen, was approved by the FDA in October 2019 for the treatment of CF in people aged 12 years and older who have at least one F508del mutation. Kaftrio (brand name of Trikafta in EU) was approved in the European Union in August 2020. It is also being evaluated in younger patients in the United States. With approval of Trikafta, Vertex can address a significantly larger CF patient population — almost 90% of patients with CF — in the future. Meanwhile, Vertex is pursuing genetic therapies to address the remaining 10% of CF patients. While CF remains the main area of focus, Vertex is also developing treatments for sickle cell disease, thalassemia and pain management.

Vertex Pharmaceuticals (VRTX) Beats Stock Market Upswing: What Investors Need to Know

Vertex Pharmaceuticals (VRTX) closed at $489.43 in the latest trading session, marking a +0.84% move from the prior day.

Is Most-Watched Stock Vertex Pharmaceuticals Incorporated (VRTX) Worth Betting on Now?

Vertex (VRTX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Kinjel Shah headshot

Vertex Stock Loses Around $3B in 3 Months: Buy the Dip or Steer Clear?

VRTX is a good stock to have in one's portfolio based on its strong overall financial performance and robust pipeline progress.

Vertex Pharmaceuticals (VRTX) Stock Sinks As Market Gains: What You Should Know

In the most recent trading session, Vertex Pharmaceuticals (VRTX) closed at $470.78, indicating a -0.07% shift from the previous trading day.

Why Is Beam Therapeutics (BEAM) Down 1.6% Since Last Earnings Report?

Beam Therapeutics (BEAM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know

Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.

The Zacks Analyst Blog Highlights Texas Instruments, Union Pacific, Vertex Pharmaceuticals, Tile Shop and Gencor

Texas Instruments, Union Pacific, Vertex Pharmaceuticals, Tile Shop and Gencor are included in this Analyst Blog.

Sheraz Mian headshot

Top Stock Reports for Texas Instruments, Union Pacific & Vertex Pharmaceuticals

Today's Research Daily features new research reports on 16 major stocks, including Texas Instruments Incorporated (TXN), Union Pacific Corporation (UNP) and Vertex Pharmaceuticals Incorporated (VRTX), as well as two micro-cap stocks Tile Shop Holdings, Inc. (TTSH) and Gencor Industries, Inc. (GENC).

Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It

Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Sundeep Ganoria  headshot

CRISPR (CRSP) Loses 24% YTD: How Should You Play the Stock?

Despite gaining regulatory approvals in many countries for the first ever CRISPR-based gene therapy, investors should remain wary of investing in CRISPR Therapeutics' (CRSP) early-stage pipeline.

Should You Invest in the VanEck Biotech ETF (BBH)?

Sector ETF report for BBH

BMY vs. VRTX: Which Stock Is the Better Value Option?

BMY vs. VRTX: Which Stock Is the Better Value Option?

Vertex (VRTX) Stock Outperforms Industry YTD: Here's Why

Vertex's (VRTX) CF sales are expected to remain strong despite a slight slowdown in the growth rate. Casgevy and suzetrigine (if approved) are set to provide the necessary diversification from the CF franchise.

The Zacks Analyst Blog Vertex Pharmaceuticals CRISPR and Moderna

Vertex Pharmaceuticals CRISPR and Moderna are included in this Analyst Blog.

Sheraz Mian headshot

Top Research Reports for NVIDIA, Home Depot & Vertex Pharmaceuticals

Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), The Home Depot, Inc. (HD) and Vertex Pharmaceuticals Incorporated (VRTX), as well as a micro-cap stock Moving iMage Technologies, Inc. (MITQ).

Kinjel Shah headshot

Here's How to Play Vertex (VRTX) Stock After Q2 Loss, Price Dip

Vertex (VRTX) is a great stock to have in one's portfolio based on its strong overall financial performance and robust pipeline progress.

Editas (EDIT) Q2 Earnings & Revenues Miss Estimates, Stock Down

Editas (EDIT) reports lower-than-expected second-quarter 2024 results as both earnings and revenues miss estimates. The stock falls 12.2%.

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

Smart Beta ETF report for IBB

CRISPR Therapeutics (CRSP) Q2 Loss Wider Than Expected

CRISPR Therapeutics (CRSP) incurs a wider-than-expected loss in the second quarter of 2024. The commercial launch of CRISPR-based gene therapy, Casgevy, is progressing well.

Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know

Recently, Zacks.com users have been paying close attention to Vertex (VRTX). This makes it worthwhile to examine what the stock has in store.

Compared to Estimates, Vertex (VRTX) Q2 Earnings: A Look at Key Metrics

Although the revenue and EPS for Vertex (VRTX) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Vertex (VRTX) Q2 Loss Wider Than Expected, '24 Sales View Raised

Vertex (VRTX) incurs a wider-than-expected loss in the second quarter while sales come in line with estimates. Vertex raises its full-year product revenue guidance.

Should You Invest in Vertex (VRTX) Based on Bullish Wall Street Views?

According to the average brokerage recommendation (ABR), one should invest in Vertex (VRTX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Vertex Pharmaceuticals (VRTX) Reports Q2 Loss, Misses Revenue Estimates

Vertex (VRTX) delivered earnings and revenue surprises of -11.57% and 0.08%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Ekta Bagri headshot

Prime Medicine (PRME) Stock: Buy or Sell Before Q2 Earnings?

While Prime Medicine's (PRME) pipeline progress is encouraging, the precarious cash position is worrisome. We advise a wait-and-watch approach before Q2 results.